Nikkei 225 dropped 0.96% to end at 28,489.13, the Kospi dropped 0.35%, and ASX 200 gained 0.48% to end at 7,474.40
Asia-Pacific markets mostly dropped on Thursday as Wall Street saw gains despite a red-hot inflation report that set market expectations for rate hikes. Meanwhile, Covid worries also came into focus as the World Health Organization (WHO) warned that omicron cases are ‘off the charts.’
Japan led losses in the region, as the Nikkei 225 dropped 0.96% to end at 28,489.13, after climbing nearly 2% on Wednesday, while the Topix shed 0.68% to 2,005.58.
Major retailers lost ground, as Seven & I dropped 3.28%, and Fast Retailing shed nearly 2%.
Over in South Korea, the Kospi dropped 0.35%.
Chinese markets deepened losses in the afternoon. The Shanghai composite tumbled nearly 1%, while the Shenzhen component dropped 1.70%. Hong Kong’s Hang Seng index shed 0.43% after rising earlier.
Shares of Chinese property developer Sunac tumbled 19% after it said in a filing that it plans to sell 452 million new shares to controlling shareholder Sunac International Investment Holdings at 10 Hong Kong dollars per share.
That will raise 4.52 billion Hong Kong dollars ($580 million), with the firm saying that 50% of the proceeds from the sale will go towards repaying loans, while the other half will be for other corporate purposes.
Genting Hong Kong shares also dropped nearly 50% after the company announced that it may not be able to pay its debts and other obligations.
Elsewhere, Australia’s ASX 200 gained 0.48% to end at 7,474.40. Financials and major miners saw gains. Rio Tinto climbed 4.13%, while BHP rose 3.83%.
In earnings, Taiwan’s TSMC reported its fourth-quarter results, posting a record 16.4% rise in quarterly profit, according to Reuters. Net profit for the quarter rose to 166.2 billion Taiwan dollars ($6 billion) from 142.8 billion Taiwan dollars a year earlier.
Investors will also keep an eye on Covid developments, as the WHO reported a record 15 million new Covid-19 cases globally for a single week, as omicron rapidly replaces delta as the dominant variant across the globe.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.